THE VALUE OF CHEMOTHERAPY IN THE IRRADIATION OF OVARIAN CARCINOMA
- 1 January 1966
- journal article
- research article
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 96 (1), 158-165
- https://doi.org/10.2214/ajr.96.1.158
Abstract
1. Combined chemotherapy and irradiation has been administered to 58 ovarian carcinoma patients, most of them advanced cases, from 1958 through 1964. 2. Nineteen of 44 patients who received Thio-TEPA plus irradiation still survive as long as 12 to 68 months after the start of treatment. 3. Patients who subsequently developed recurrences usually responded to a second course of chemotherapy. 4. These results, as well as the duration of the original period of remission, are an improvement over those previously obtained without the benefit of chemotherapy at this institution. 5. The additional morbidity associated with this approach is deemed acceptable.This publication has 6 references indexed in Scilit:
- Hemisulfur Mustard in the Palliation of Patients with Metastatic Ovarian CarcinomaObstetrics & Gynecology, 1959
- Triethylenethiophosphoramide (Thio-TEPA) in the treatment of neoplastic diseaseCancer, 1957
- Chemotherapy of Solid Tumors with Triethylene ThiophosphoramideNew England Journal of Medicine, 1955
- TRIETHYLENE MELAMINE IN THE MANAGEMENT OF FAR ADVANCED OVARIAN CANCER1955
- Clinical studies of triethylenethiophosphoramide in the treatment of inoperable cancerCancer, 1955
- TREATMENT OF LEUKEMIA WITH TRIETHYLENE THIOPHOSPHORAMIDE (THIO-TEPA)A.M.A. Archives of Internal Medicine, 1953